It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial.

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial. MET-097i ...

The concentrations of adiponectin, low-density lipoprotein-cholesterol (LDL-c), total cholesterol (TC), glucagon-like peptide 1 (GLP-1 ... The circle˚ or the symbol * represents the outliers in the ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide-1 (GLP-1) receptors. Sales of semaglutide ...

Company announcement - No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeli ...

Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some ...